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Introduction
Urothelial bladder cancer (UBC) results in considerable clini-
cal input and necessitates ongoing research to reduce the bur-
den of patients and health care providers.1 Current era of 
genomics offers new insights into UBC pathogenesis.2 
However, due to the complex nature of genetics, many studies 
are difficult to summarize into clear recommendations for 
future research and clinical practice.
Urothelial bladder cancer is most frequently diagnosed as 
a non-muscle-invasive bladder cancer (NMIBC), accounting 
for 70% to 80% of all new cases.3 Management of NMIBC is 
complex with appropriate treatment dependent on multiple 
clinical and pathological components. Importantly, a signifi-
cant proportion of patients are prone to tumor recurrence 
and/or progression, both events being difficult to predict. 
Previously developed multifactorial prognostic NMIBC 
tools4 have been useful to describe populations, but lack accu-
racy for individual outcomes and require further advances.5 
Muscle-invasive bladder cancer (MIBC) cases are equally 
complex to treat with various permutations of chemotherapy, 
radiotherapy, and cystectomy,6 with an addition of recent ini-
tiatives in molecular-genomic subtyping.2
Although multiple studies have addressed the potential role 
of genetic variation in UBC prognosis, the findings are yet to 
be implemented into clinical practice. For the most part, 
genetic associations are often reported in small samples and 
their validity is difficult to establish.7 In addition, the interpre-
tation of the biological relevance over many reports is challeng-
ing. Furthermore, it is not yet clear whether genetic associations 
overlap within and between the groups of direct (recurrence, 
progression, survival) and indirect (stage, grade, tumor size, age 
at the time of diagnosis) prognostic endpoints. Identifying 
existing genetic similarities between prognostic outcomes 
would help potentially decipher underlying pathological 
mechanisms and guide promising future directions in UBC 
research.
In this review, our objective is to summarize genetic associa-
tions for UBC prognostic phenotypes and to describe any 
overlap or existing patterns that would clarify their pertinence 
for future clinical practice.
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ABSTRACT
InTRodUCTIon: Many germline associations have been reported for urinary bladder cancer (UBC) outcomes and prognostic characteris-
tics. It is unclear whether there are overlapping genetic patterns for various prognostic endpoints. We aimed to review contemporary litera-
ture on genetic associations with UBC prognostic outcomes and to identify potential overlap in reported genes.
MeThodS: EMBASE, MEDLINE, and PubMed databases were queried for relevant articles in English language without date restrictions. 
The initial search identified 1346 articles. After exclusions, 112 studies have been summarized. Cumulatively, 316 single-nucleotide polymor-
phisms (SNPs) were reported across prognostic outcomes (recurrence, progression, death) and characteristics (tumor stage, grade, size, 
age, risk group). There were considerable differences between studied outcomes in the context of genetic associations. The most commonly 
reported SNPs were located in OGG1, TP53, and MDM2. For outcomes with the highest number of reported associations (ie, recurrence and 
death), functional enrichment annotation yields different terms, potentially indicating separate biological mechanisms.
ConClUSIonS: Our study suggests that all UBC prognostic outcomes may have different biological origins with limited overlap. Further 
validation of these observations is essential to target a phenotype that could best predict patient outcome and advance current management 
practices.
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Methods
The systematic review was conducted according to the 
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA)8 (Supplementary Table 1).
We queried EMBASE, Medline, and PubMed with the fol-
lowing search term: ((“urinary bladder neoplasms” OR “blad-
der cancer” OR “urothelial carcinoma”) AND (prognosis OR 
survival OR recurrence OR progression OR grade OR stage 
OR “tumour size” OR age) AND (polymorphi* OR SNP OR 
germline)). The search was limited to articles published prior 
to November 13, 2018, written in English, and describing 
human research only. A detailed flowchart on the selection and 
search process is presented in Figure 1. Reference lists of 
included manuscripts were checked for potentially missing 
reports. Study eligibility was determined by the 2 authors 
(N.L., A.W.).
Inclusion criteria were as follows:
1. Studies assessing single germline single-nucleotide poly-
morphism (SNP) variants (not somatic mutations, 
insertion/deletions, microsatellites, haplotype analyses, 
dinucleotide polymorphism associations, multiple SNP 
prediction models);
2. Original reports (not meta-analyses, reviews, letters, case 
reports, others);
3. Studies focused on UBC or where UBC data are 
described distinctly from a broader urothelial carcinoma 
(UC) cohort;
4. Studies reporting an effect size;
5. Studies reporting significant associations (for character-
istics or prognosis);
6. DNA sequence level variation described;
7. The described SNPs could be identified.
Studies describing diagnostic and methodological proce-
dures and gene-gene and gene-environment interactions were 
excluded.
Each study was assessed for quality by evaluating report-
ing adequacy. Inconsistency was regarded as mismatching 
data within the study (eg, different SNP IDs reported in 
Figure 1. Flow diagram of study selection used in evidence synthesis. SNP indicates single-nucleotide polymorphism.
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article sections). Data completeness was verified if all rele-
vant data fields for a genetic association study9 were available 
to extract from the report. The quality criteria were part of 
the study selection process (eg, studies stating variant rele-
vance for an outcome without providing an effect size were 
regarded as having low quality and excluded from further 
evaluation).
Data extraction
Further information was extracted from each eligible study: 
year of publication, first author, patient subgroup (UBC, 
MIBC, NMIBC, or other), cancer subtype (UC or other), eth-
nicity, sample size, SNP ID, locus, gene, effect allele, reference 
allele, effect allele frequency, effect size, corresponding 95% 
confidence intervals, and P value.
Summarizing overlap in genetic associations and 
outcomes
To investigate whether previously reported genes may play a 
role across multiple UBC outcomes, results were put in a 
ranked table. Genes associated with many UBC endpoints 
were ranked high, whereas genes that were reported for one or 
few of the outcomes were ranked low. As such, we were able to 
suggest genes that are important for UBC prognosis overall (ie, 
ranked high) and which genes are more likely to be outcome 
specific (eg, only associated with cancer recurrence and ranked 
low).
The resulting ranking acted as a guideline for identifying 
genes that were commonly observed for most of the prognostic 
outcomes and characteristics. Outcomes with at least 20 genes 
were chosen and their functional roles were further described 
in additional detail.
Functional annotation
After summarizing the overlap, some outcomes have been 
associated with multiple genes. Every biological process is 
polygenic, and having bigger sets of identified genes helps elu-
cidate biological pathways behind the studied phenotype. We 
chose outcomes with the largest number of reported genes and 
submitted those sets to the DAVID Functional Annotation 
Tool.10 This tool groups genes by their functional similarity, 
using information from well-known databases, such as Gene 
Ontology (GO) for biological mechanisms and KEGG (Kyoto 
Encyclopedia of Genes and Genomes) for pathways, among 
others. Gene clustering was performed with setting the highest 
level of classification stringency. A high level of stringency gen-
erates fewer clusters, but genes within them are associated 
more tightly. Moreover, to reduce the likelihood of describing 
false-positive clusters, only gene groups containing pathways 
with false discovery rates (FDRs) < 5% were interpreted as 
valid results.
Statistical analysis
Overall, our search has resulted in multiple genes correspond-
ing to various outcomes. As such, the resulting data are very 
difficult to describe in a comprehensive manner. To reduce the 
dimensionality of current data, we performed a principal com-
ponent analysis (PCA). Principal component analysis can be 
seen as a form of an exploratory analysis to identify group-level 
correlations in the sample. It is a useful tool for improving the 
interpretation of data, as it allows visualizing similarities 
between groups regarding chosen characteristics. In our analy-
sis, we aimed to investigate the similarity between UBC out-
comes regarding their genetic background. For example, clinical 
outcomes that share genes would plot more closely, whereas an 
outcome that does not share any genes with other endpoints 
would plot far from other groups. In the currently reviewed 
literature, some outcomes have been investigated more often 
(eg, recurrence and death), and hence we have adjusted the size 
of data points in a PCA plot to be relative to the number of 
associated genes. The first 2 principal components were plotted 
for all studied endpoints.
Results
For this review, 373 full-text articles were evaluated in depth, 
resulting in a final set of 112 articles for further summary (Figure 
1). In total, 316 associations were extracted across all investigated 
outcomes as follows: age (N = 1211-22), stage (N = 7911,13,18,20,23-66), 
tumor size (N = 267,68), grade (N = 4911,18,27,29,32,33,35-37,42,47,50,54, 
58,62,66,67,69-75), risk groups (N = 1512,14,17,24,25,30,31,33,40,76,77), recurrence 
(N = 8114,23,25,30,31,40,43,49,50,52,53,69,71,78-107), progression (N = 2426,33 
,46,87-89,107-112), and death (N(cancer-specific) = 1234,43,46,101,107,113-
117, N(overall) = 4234,43,50,56,89,90,111,112,118-122).
There was considerable heterogeneity across all associations, 
including assumed patterns of inheritance, studied ethnic pop-
ulations, and outcome definitions.
Age was investigated using multiple year cut-offs, namely, 
50,13 56,17 60,11,16,22 65,12,15,18-21 and once as a continuous vari-
able14 (Supplementary Table 2).
Tumor size was investigated either as using a cut-off of 
⩾3 cm67 or defined as a large tumor, corresponding to stages 
T1 to T468 (Supplementary Table 3).
Tumor stage was analyzed using multiple combinations. 
Broadly, we have differentiated between stages corresponding 
to NMIBC and MIBC cases. For studies reporting on NMIBC, 
the following endpoints were used: tumors of Tis,61,65  
T1,37 Ta + T1,13,18,36,39,54,58,62-64,66 and Ta + T1 + Tis32,59,60 
(Supplementary Table 4). As for MIBC, most studies have 
defined the primary outcome as T2+ staged tum
ors.11,20,23-32,34-57 However, some associations have been 
reported for a merged group of T2+ and T1 stages.33,34
Most reports on grade can be roughly categorized into con-
taining either low- or high-grade UBC cases. Low-grade UBC 
definitions were as follows: G1,18,54,62,70 G2,35,58,62,70 G1 + G2,36 
low-grade,69,71 and G1 + G2 + papilloma.32 High-grade UBC 
4 Biomarkers in Cancer 
was usually defined as grade 3 UBC,11,27,29,32,36,37,47,50,67,70,72-75 a 
combination of G2 and G3 NMIBC,54,66 and some studies 
have reported estimates for grade 4 tumors, without a reference 
for the grading system used (G3 + G442 and G2 + G3 + G4)33 
(Supplementary Table 5).
It was common for studies to classify UBC as a disease of 
low or high risk that corresponded to various combinations of 
clinical stage and grade. For low-risk tumors, researchers used 
the following definitions: TaG2,33,34 TaG1,33 and TaG1-
2.12,14,17 In contrast, high-risk tumors were defined as TaG2-
3 + T1G1-3,25,30,31,40,76 TaG3 + T1G2-3,24 G2-3 with T1-4,77 
and TaG3 + T133 (Supplementary Table 6).
For genetic associations with tumor recurrence, studies mostly 
focused on NMIBC cases (except for few reports considering 
UBC group overall49 or MIBC).50,71 The NMIBC recurrence was 
investigated as an overall outcome,49,69,78,89,90,94,97,104,106 or in spe-
cific groups: patients younger than 64 years,98 patients not treated 
with Bacillus Calmette-Guérin (BCG) therapy40,43; BCG-treated 
patients23,25,30,31,40,43,52,53,79-83,85-87,93,95,96,99,100,102,103,107; patients 
treated only with transurethral urinary bladder tumor (TURBT) 
resection88,101; patients who have received both TURBT and 
BCG treatments91,92; patients having received treatments of 
TURBT and epirubicin105; and recurrence only among low-risk 
NMIBC14,84 (Supplementary Table 7).
Progression was defined as an increase of stage within 
NMIBC33,109,110 or UBC108 overall. Also, transition from 
NMIBC to MIBC or metastatic disease87-89 was considered a 
disease progression, sometimes expanding the latter definition 
to include cancer-specific death.107,112 In other cases, alterna-
tive definitions were considered, namely, occurrence of metas-
tases26,46 and a confirmed relapse among MIBC111 
(Supplementary Table 8).
Regarding death outcomes, there were 2 broad groups of 
overall33,43,56,89,90,112,118-121 and cancer-specific34,43,46,101,107,113-117 
survival endpoints (Supplementary Table 9).
Retrieved data and detailed study characteristics, including 
outcome definition for each study, are presented in 
Supplementary Tables 2 to 9.
Overlap between outcomes
A summary table of existing overlap between outcomes and 
associated genes is presented in Table 1.
OGG1 was the most commonly reported gene, having been 
associated with patient age,19 tumor stage,54 grade,54 recur-
rence,40,78 and risk group.40 Associations on OGG1 and UBC 
did not cluster within a clearly defined subgroup and instead 
showed relationships with various characteristics: increased age 
at diagnosis (>65 years)19 and elevated risks of the following: 
non-muscle-invasive and invasive UBC,54 low- and high-grade 
tumors,54 rate of recurrence,40,78 and high-risk tumors.40
A set of 2 genes (TP53 and MDM2) have also been reported 
for multiple endpoints, specifically UBC grade,42,69 stage,25,41,42 
recurrence,25,69,101 survival,101,117 and risk group.25,76 For most 
outcomes (death, risk category, grade, stage), the associations 
for MDM2- and TP53-related variants were in opposite 
directions.
Regarding the number of genes corresponding to a single 
endpoint, tumor recurrence was the outcome with the highest 
sum of genes (N = 28) showing associations, followed by death 
(N = 21) (Table 1).
To elucidate any unifying pathways between these genes, 
gene sets for recurrence and death were submitted to the func-
tional annotation tool DAVID.10
For recurrence, DAVID identified 2 gene clusters of similar 
functions that contained pathways with acceptable FDR values 
(Supplementary Table 10). The first group (enrichment 
score = 2.72) was formed entirely of RGS family genes (RGS10, 
RGS13, RGS16). The second cluster (enrichment score = 2.42) 
was formed by GLI2, GLI3, and SHH genes. Out of 10 func-
tional terms within the cluster, 1 was of satisfactory FDR and 
reached Bonferroni-adjusted statistical significance < .05, 
termed “hindgut morphogenesis.”
For individual enriched pathways, 20 have yielded 
FDR < 5% and are listed in Supplementary Table 11. Three 
functional terms—“hindgut morphogenesis,” “pathways in 
cancer,” and “positive regulation of transcription from RNA 
polymerase II promoter”—have shown low FDR rates and 
were also below the conventional level of statistical significance 
(P < .05) after multiple-comparison adjustment.
For genes associated with UBC survival, the submitted set 
retrieved 6 functional clusters in total; however, no individual 
terms had acceptable FDR values.
Nonetheless, multiple individual functional pathways with 
FDR < 5% were identified instead (Supplementary Table 12). 
One term, “pancreatic cancer,” has reached a Bonferroni-
adjusted statistical significance (P = .05).
Finally, a performed PCA analysis for previously reported 
genetic associations showed UBC recurrence to be the most 
distinct outcome (Figure 2), with tumor stage and grade also 
showing significant deviations from other endpoints.
Discussion
In this review, we have summarized existing evidence for single 
SNP genetic associations with UBC characteristics (tumor 
size, stage, grade, patient’s age) and prognostic outcomes 
(recurrence, progression, survival). There were multiple associ-
ations for considered endpoints with limited overlap. Based on 
these data, we have made several observations.
It is widely accepted that complex disease genetic archi-
tecture is highly polygenic.123 However, the currently sum-
marized list of associations for UBC outcomes and 
characteristics is far from exhaustive. It is essential to note 
that future studies with higher per-study power will contrib-
ute additional associations and will clarify the validity of 
those already reported.
Lipunova et al 5
Table 1. Overlap between reported outcomes and mapped genes.




Age/grade/recurrence/risk group/stage 1 OGG1
Death/grade/recurrence/risk group/stage 2 TP53, MDM2
Age/grade/risk group/stage 1 CCND1
Age/recurrence/risk group/stage 1 XRCC7(PRKDC)
Age/death/recurrence/stage 1 XRCC1
Grade/progression/risk group/stage 1 HRAS
Death/grade/recurrence/stage 2 PDCD6, XPD(ERCC2)
Age/grade/stage 1 H19
Age/death/stage 1 EGFR
Grade/risk group/stage 1 MSH6
Death/risk group/stage 1 NQO1
Progression/recurrence/stage 1 MIR146A
Death/grade/recurrence 1 IL6
Grade/recurrence/tumor size 1 TSP-1(THBS1)
Death/progression/recurrence 1 NOS3
Age/recurrence/risk group 1 TACC3/FGFR3
Death/grade/stage 2 RAD51, MTHFR
Recurrence/risk group/stage 2 CASP9, IL18
Grade/recurrence/stage 4 CCR2, PPARG, GSTP1, XPC




Age/risk group 2 CASC11, TP63
Death/stage 2 TLR10, IL27
Death/recurrence 3 RGS2, GSTO1, XPF(ERCC4)
Grade/stage 4 LEPR, IGFBP3, XPG(ERCC5), PSCA
Recurrence/stage 4 IL17A, TNFA, GPX1, NAMPT
Death/progression 4 NOD2, BCL2, RGS5, ERCC1
Tumor size 1 WISP1(CCN4)
Risk group 2 POLG2, BRCA2
Age 3 PCAT1, POR, HOTAIR
Grade 6 MIR143_CARMN, TMEM129_TACC3_FGFR3, CLPTM1L, MYC, 
TNFRSF10A(TRAILR1, DR4), CCNE1
Progression 9 DGCR8, NOS2, CDKN2A, TGFB1, RGS4, RGS7, IL10, UNG, RGS14
(Continued)
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Importantly, our review underscores the sensitivity of out-
come definition in genetic studies. It has been demonstrated 
that genetic variants for UBC risk are unlikely to be relevant 
for prognosis,124 and our report implies that prognostic out-
comes demonstrate further within-group heterogeneity. 
Interestingly, the PCA revealed differences for direct prog-
nostic outcomes: UBC death and progression showed similar 
characteristics, whereas UBC recurrence significantly devi-
ated from the group. From a biological perspective, cancer 
recurrence is not an equivalent to progression or death, and it 
is likely that the mechanisms involved are triggered and 
organized via different pathways. Similarly, tumor character-
istics (grade, stage, size) and patient characteristics (age) are 
likely different entities in genetic contribution.
When trying to elucidate unifying pathways for multiple 
genes involved in certain outcomes, UBC recurrence was found 
to be associated with terms that relate to the formation of a 
new tissue (eg, “hindgut morphogenesis”). In contrast, func-
tional pathway terms were different for death as an outcome 
and may indicate a separate biological mechanism. Interestingly, 
the most promising associated term for death was “pancreatic 
cancer,” which exhibits very low survival rates in comparison 
with cancers of any other site.125
In the light of our analyses, UBC prognosis may represent a 
complex phenotype, and this review indicates that different 
outcomes imply distinct genetic associations. The genetic rela-
tionships may overlap but, nonetheless, should be treated as 
independent endpoints.
Importantly, the review identifies a number of commonly 
reported genes, specifically OGG1, TP53, and MDM2. OGG1 
encodes a protein involved in base excision repair (BER) path-
ways to protect cells from oxidative stress.126 Although having 
a clear role in mutagenic processes, OGG1-null mice showed 
only moderate increases in malignancy rate, likely due to effec-
tive alternative damage repair pathways.127 Evidence from 
multiple meta-analyses128-130 of OGG1 involvement in UBC 
cancerogenesis is contradictory, and, when having a genuine 
effect, is more likely to play a supporting role in a multi-stage 
process rather than being the main cause of it.127 It is also prob-
able that the establishment of the type and direction of genetic 
associations requires larger populations (underscoring suffi-
cient sample sizes for different ethnicities), not yet available to 
researchers.
In addition, the link between TP53 and MDM2 genes has 
been extensively reported in the literature, offering an attrac-
tive pharmacologic target in cancer treatment.131 P53 protein 
acts as a tumor suppressor, which is negatively regulated by 
MDM2 oncoprotein. The pattern is somewhat mirrored in 
observed associations, where a variation in SNPs of the 2 
genes seemed to correspond to effects in opposite direction 
(eg, SNPs in TP53 increased the risk of T2+ stage, whereas 
alterations in MDM2 showed reduced risk of invasive 
tumors).
Collectively, OGG1, TP53, and MDM2 are relevant for 
multiple essential DNA-preserving cellular mechanisms and 
Figure 2. Principal component analysis for genetic associations with 
urinary bladder outcomes.
Data point sizes are indicative of the number of associated genes with each 
outcome. The first 2 plotted principal components include all genetic reports and 
explain most of the variance in all plotted outcomes.




Stage 15 CD44, SDF1(CXCL12), CXCR4, SLC23A1, MATR3, DNAJC18, 
C13ORF31(LACC1), CD4, CFH, XRCC3, IL22, MMP12, COX2(PTGS2), 
P21(CDKN1A), PMS2
Death 20 IL8RB(CXCR2), RPTOR, RGS12, GSTO2, MRE11, RB1CC1, EPHX1, BCL2L1, 
GATA3, UGT1A1, XRCC4, PIK3R1, DRD4, RGS3, TERT, CD80, AURKA, 
AKT2, TGFBR1, GNB3
Recurrence 26 vDR, Survivin(BIRC5), MMP2, GPX4, NFKBIA, CDH1, IGF1, GLI2, NEIL2, 
GLI3, RNASEN(DROSHA), IL8(CXCL8), ICAM1, IFN-G, SHH, RGS13, RGS16, 
RGS10, DDX20, GSS, CWC27, SOD1, ERCC6, NRAMP1(SLC11A1), ALDH2, 
TNFRSF10A(TRAILR1, DR4)
Table 1. (Continued)
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hence would be expected to have importance for a variety of 
UBC characteristics and outcomes, as observed in our review.
The limitations of our study are important to acknowledge. 
Many reports have analyzed different ethnicities, which alone 
does not undermine the reported associations, but makes inter-
population relevance improbable due to differing allele frequen-
cies.132 Moreover, assumed genetic patterns of inheritance (eg, 
recessive, dominant, additive) differed highly between the stud-
ies, without a clear preference for the chosen model. Usually, the 
reported model was chosen ad hoc as a consequence of being 
statistically significant, making it difficult to be confident that 
the reported model reflected true genetic architecture of the 
association. Because associations were highly heterogeneous, we 
were unable to perform a meta-analysis (which would have pro-
vided a preferred summary of these data). Furthermore, most of 
the included studies were of candidate-gene design; we would 
expect different results if all studies followed an agnostic 
genome-wide association approach. Finally, sample sizes were 
limited, and it is difficult to establish whether all reported asso-
ciations are robust. The lack of external replication studies for 
genetic associations is detrimental to translating science into 
practice, as many genetic findings are likely to be false positives.7 
Optimally, only validated variants would be included in review 
studies. We underscore the importance of validation efforts for 
future studies to summarize only unambiguous variants.
Finally, we interpret this report as exploratory in its nature, and 
although no clear guidelines can be drawn due to the heterogene-
ity of previous studies, it is nonetheless an important exercise in 
drawing research directions. First of all, as more independent 
research groups have access to genotype data of bladder cancer 
patients, this article can prove a useful resource to replicate already 
reported associations in a time-efficient manner. Second, report-
ing those results will help identify which associations and corre-
sponding genetic regions are most promising to pursue in other 
studies. As such, the landscape of genetic bladder cancer investi-
gations may be accelerated by collaborative contributions made 
by the wider research community and preserve resources for stud-
ies of higher likelihood to produce meaningful results.
To conclude, we have summarized existing genetic associa-
tions for tumor and patient characteristics and disease progno-
sis for UBC. Multiple loci have been identified that demonstrate 
little consensus and highlight the possibility of UBC prognos-
tic outcomes being unique entities in the context of genetic 
contribution. We recommend that further replication of previ-
ously identified SNPs should be undertaken. Consecutive for-
mal reviews of existing associations will help facilitate their 
potential use in clinical practice.
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